Highlights
- Good Manufacturing Practice (GMP) manufacturing has been completed, enabling treatment of the first patient in the Phase 1/2 CHM CDH17 CAR-T trial.
- Additional clinical sites are expected to open in the second half of 2024.
- CHM shares surged by 11% following the update.
Shares of Chimeric Therapeutics Limited (ASX:CHM) jumped over 11% during early morning trading on 16 August 2024, reaching AU$0.019 apiece. This uptick followed the company’s announcement of progress in its Phase 1/2 CHM CDH17 CAR-T trial. GMP manufacturing has been completed, paving the way for the treatment of the first participant in the trial.
The cells of the clinical trial participant were collected at the Sarah Cannon Cancer Centre in Nashville, and then sent to the contract manufacturing facility. Following GMP manufacturing, the CHM CDH17 CAR-T cells successfully passed specification testing and quality assurance review. They are in transit to the clinical trial site for infusion.
Details of the Phase 1/2 CHM CDH17 CAR-T trial
The Phase 1/2 clinical trial is designed to determine the recommended Phase 2 dose of the first-in-class, third generation CHM CDH17 CAR T. This two-stage study aims to assess both the safety and objective response rate in patients with advanced intestinal neuroendocrine tumours, as well as colorectal and gastric cancer.
The company plans to open additional clinical sites in the latter half of 2024.
.